Healthcare
Live Price
Offline$5.38
+0.56% today
1Y Change
-3.76%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Valneva SE (VALN) is a Healthcare stock with a market cap of $370.00M and listed on NASDAQ. The stock last traded around $5.38 and down 3.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +3.0%, EPS growth of -656.9%, a dividend yield of 0.0%. What stands out right now is revenue +3.0%, EPS -656.9%, free cash flow +31.4% with operating margin -50.3% and ROIC -27.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VALN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VALN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VALN Max Drawdown
-57.62%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VALN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$348.1M
-3.7% YoY
FY Net Income
-$73.4M
+48.8% YoY
Free Cash Flow
-$16.3M
+94.1% YoY
Revenue Growth
+3.0%
EPS Growth
-656.9%
Gross Margin
38.7%
Net Margin
-66.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 175M | 170M | 154M | 361M | 348M |
| Gross Profit | 68M | 71M | 53M | 37M | 160M |
| Operating Income | -82M | 13M | -82M | -113M | -61M |
| EBITDA | -50M | 32M | -58M | -105M | -39M |
| Net Income | -115M | -12M | -101M | -143M | -73M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 110M | 168M | 126M | 289M | 347M |
| Total Assets | 399M | 500M | 460M | 621M | 817M |
| Total Liabilities | 293M | 319M | 332M | 402M | 647M |
| Shareholder Equity | 106M | 181M | 128M | 220M | 171M |
| Total Debt | 207M | 216M | 209M | 152M | 115M |
| Net Debt | 98M | 48M | 83M | -137M | -232M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
77M
+131.3% YoY
Capital Expenditures
93M
-217.8% YoY
Free Cash Flow
16M
+94.1% YoY
Key ratios
Gross Margin
38.7%
Operating Margin
-50.3%
Net Margin
-66.0%
ROE
-74.5%
Debt / Equity
1.95x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.